Homologous Recombination Deficiency Detection Algorithms: A Systematic Review

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Dec 9

PMID 38067337

Authors

Lasse Ringsted Mark

Simone Karlsson Terp

Henrik Bygum Krarup

Mads Thomassen

Inge Sokilde Pedersen

Martin Bogsted

Affiliations

Soon will be listed here.

Abstract

Homologous recombination deficiency (HRD) can arise from germline or somatic pathogenic variants as well as other genomic damage and epigenetic alterations in the HR repair pathway. Patients with tumors presenting with an HRD phenotype can show sensitivity to Poly (ADP-ribose) polymerase inhibitors (PARPis). Several promising tests to detect HRD have been developed based on different HRD definitions, biomarkers, and algorithms. However, no consensus on a gold standard HRD test has been established. In this systematic review, a comprehensive list of tests for the detection of HRD was identified and compared regarding HRD definition, biomarkers, and algorithms. PubMed's Medline and Elsevier's Embase were systematically searched, resulting in 27 eligible articles meeting the inclusion criteria. The primary challenge when comparing HRD tests lies in the lack of a consensus definition of HRD, as the HRD definition influences the proportion of samples being classified as HRD and impacts the classification performance. This systematic review provides an overview of available HRD tests that can inspire other researchers in searching for a gold standard HRD definition and highlights the importance of the factors that should be considered when choosing an HRD definition and tests for future planning of clinical trials and studies.

Citing Articles

Genomic scarring score predicts the response to PARP inhibitors in non-small cell lung cancer.

Tsilingiri K, Chalari A, Christopoulou G, Voutsina A, Constantoulakis P, Potaris K NPJ Precis Oncol. 2024; 8(1):291.

PMID: 39725687 PMC: 11671589. DOI: 10.1038/s41698-024-00777-6.

The coexistence of a BRCA2 germline and a DICER1 somatic variant in two first-degree cousins suggests their potential synergic effect.

Del Baldo G, Mastronuzzi A, Cipri S, Agolini E, Matraxia M, Novelli A Sci Rep. 2024; 14(1):21435.

PMID: 39271738 PMC: 11399136. DOI: 10.1038/s41598-024-71667-x.

References

Leibowitz B, Dougherty B, Bell J, Kapilivsky J, Michuda J, Sedgewick A . Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort. BMC Cancer. 2022; 22(1):587. PMC: 9148513. DOI: 10.1186/s12885-022-09669-z. View

Qu S, Martens J, Hollestelle A, Smid M . Identifying Transcripts with Tandem Duplications from RNA-Sequencing Data to Predict BRCA1-Type Primary Breast Cancer. Cancers (Basel). 2022; 14(3). PMC: 8833645. DOI: 10.3390/cancers14030753. View

Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D . Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009; 374(9698):1331-8. DOI: 10.1016/S0140-6736(09)61157-0. View

Tibshirani R, Hastie T, Narasimhan B, Chu G . Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A. 2002; 99(10):6567-72. PMC: 124443. DOI: 10.1073/pnas.082099299. View

Diossy M, Reiniger L, Sztupinszki Z, Krzystanek M, Timms K, Neff C . Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors. Ann Oncol. 2018; 29(9):1948-1954. PMC: 6158763. DOI: 10.1093/annonc/mdy216. View

Joosse S, Brandwijk K, Devilee P, Wesseling J, Hogervorst F, Verhoef S . Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH. Breast Cancer Res Treat. 2010; 132(2):379-89. DOI: 10.1007/s10549-010-1016-7. View

Miller R, Leary A, Scott C, Serra V, Lord C, Bowtell D . ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol. 2020; 31(12):1606-1622. DOI: 10.1016/j.annonc.2020.08.2102. View

Welcsh P, King M . BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet. 2001; 10(7):705-13. DOI: 10.1093/hmg/10.7.705. View

Smyth E, Cafferkey C, Loehr A, Waddell T, Begum R, Peckitt C . Genomic loss of heterozygosity and survival in the REAL3 trial. Oncotarget. 2019; 9(94):36654-36665. PMC: 6291175. DOI: 10.18632/oncotarget.26336. View

10.

Nguyen L, Martens J, Van Hoeck A, Cuppen E . Pan-cancer landscape of homologous recombination deficiency. Nat Commun. 2020; 11(1):5584. PMC: 7643118. DOI: 10.1038/s41467-020-19406-4. View

11.

Murai J, Huang S, Das B, Renaud A, Zhang Y, Doroshow J . Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012; 72(21):5588-99. PMC: 3528345. DOI: 10.1158/0008-5472.CAN-12-2753. View

12.

Lips E, Laddach N, Savola S, Vollebergh M, Oonk A, Imholz A . Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness. Breast Cancer Res. 2011; 13(5):R107. PMC: 3262220. DOI: 10.1186/bcr3049. View

13.

Lee D, Seung H . Learning the parts of objects by non-negative matrix factorization. Nature. 1999; 401(6755):788-91. DOI: 10.1038/44565. View

14.

Zhang S, Yuan Y, Hao D . A genomic instability score in discriminating nonequivalent outcomes of BRCA1/2 mutations and in predicting outcomes of ovarian cancer treated with platinum-based chemotherapy. PLoS One. 2014; 9(12):e113169. PMC: 4249855. DOI: 10.1371/journal.pone.0113169. View

15.

Coleman R, Fleming G, Brady M, Swisher E, Steffensen K, Friedlander M . Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med. 2019; 381(25):2403-2415. PMC: 6941439. DOI: 10.1056/NEJMoa1909707. View

16.

Popova T, Manie E, Rieunier G, Caux-Moncoutier V, Tirapo C, Dubois T . Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res. 2012; 72(21):5454-62. DOI: 10.1158/0008-5472.CAN-12-1470. View

17.

Telli M, Timms K, Reid J, Hennessy B, Mills G, Jensen K . Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clin Cancer Res. 2016; 22(15):3764-73. PMC: 6773427. DOI: 10.1158/1078-0432.CCR-15-2477. View

18.

Zhuang S, Chen T, Li Y, Wang Y, Ai L, Geng Y . A transcriptional signature detects homologous recombination deficiency in pancreatic cancer at the individual level. Mol Ther Nucleic Acids. 2021; 26:1014-1026. PMC: 8571416. DOI: 10.1016/j.omtn.2021.10.014. View

19.

Severson T, Wolf D, Yau C, Peeters J, Wehkam D, Schouten P . The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting. Breast Cancer Res. 2017; 19(1):99. PMC: 5574249. DOI: 10.1186/s13058-017-0861-2. View

20.

Lu J, Wu D, Li C, Zhou M, Hao D . Correlation between gene expression and mutator phenotype predicts homologous recombination deficiency and outcome in ovarian cancer. J Mol Med (Berl). 2014; 92(11):1159-68. DOI: 10.1007/s00109-014-1191-9. View